Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBIT Margin (2023 - 2025)

Historic EBIT Margin for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 3068.97%.

  • CG Oncology's EBIT Margin rose 627333600.0% to 3068.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 8285.33%, marking a year-over-year increase of 57456700.0%. This contributed to the annual value of 10067.25% for FY2024, which is 171136300.0% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's EBIT Margin is 3068.97%, which was up 627333600.0% from 81161.54% recorded in Q1 2025.
  • CG Oncology's EBIT Margin's 5-year high stood at 3068.97% during Q3 2025, with a 5-year trough of 1935500.0% in Q4 2023.
  • Its 3-year average for EBIT Margin is 253606.61%, with a median of 23290.99% in 2024.
  • As far as peak fluctuations go, CG Oncology's EBIT Margin skyrocketed by 2000000000bps in 2024, and later crashed by -769140900bps in 2025.
  • CG Oncology's EBIT Margin (Quarter) stood at 1935500.0% in 2023, then skyrocketed by 100bps to 8344.08% in 2024, then skyrocketed by 63bps to 3068.97% in 2025.
  • Its last three reported values are 3068.97% in Q3 2025, 81161.54% for Q1 2025, and 8344.08% during Q4 2024.